The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review

Abstract

Hastono Ridwansyah, Achmad Hussein S. Kartamihardja, Muhammad Hasan Bashari, Bethy

The treatment of B-cell non-Hodgkin lymphoma (NHL) still has the problems, such as a high rate of relapse and refractory case. The use of radioimmunotherapy (RIT) appears to be a treatment modality expected to resolve the problem. However, RIT remains underused in a clinical practice setting for B-cell NHL treatment. This study was conducted to find out the treatment potency of RIT in patients with B-cell lymphoma, particularly in indolent or aggressive NHL patients. This literature review was conducted in a systematic review from many kinds of literature published from 2010 to 2020 using keyword combinations, including “radioimmunotherapy”, “aggressive lymphoma”, “diffuse large B-cell lymphoma”, “indolent lymphoma”, and “follicular lymphoma”. Those keywords were entered in the advanced search of Cochrane Library and Pubmed. There were 84 articles collected based on those keywords and among them, only 30 articles containing antibody anti-CD20 fulfilled the inclusion and exclusion criteria. Articles reporting the efficacy and safety of RIT as the first-line and consolidation of aggressive and indolent lymphoma were 5 and 11 articles respectively, and as relapsed/refractory treatment were 9 and 5 articles, respectively. Radiopharmaceuticals used were 90Y-ibritumomab-tiuxetan, 131I-tositumomab, and 131I-rituximab. The conclusion is that RIT, mainly 90Y-ibritumomab tiuxetan, has shown favorable and safe clinical outcomes for indolent and aggressive B-cell NHL, and it has a greater opportunity of being used as B-cell NHL treatment to improve ORR and overall patient survival in a clinical practice setting.

How to Cite this Article
Pubmed Style

Ridwansyah H, Kartamihardja AHS, Bashari MH, Hernowo BS. The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. SRP. 2021; 12(1): 935-947.
doi:10.31838/srp.2021.1.131

Web Style

Ridwansyah H, Kartamihardja AHS, Bashari MH, Hernowo BS. The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. http://www.sysrevpharm.org/?mno=45560 [Access: March 30, 2021]. doi:10.31838/srp.2021.1.131

AMA (American Medical Association) Style

Ridwansyah H, Kartamihardja AHS, Bashari MH, Hernowo BS. The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. SRP. 2021; 12(1): 935-947. doi:10.31838/srp.2021.1.131



Vancouver/ICMJE Style

Ridwansyah H, Kartamihardja AHS, Bashari MH, Hernowo BS. The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. SRP. (2021), [cited March 30, 2021]; 12(1): 935-947. doi:10.31838/srp.2021.1.131



Harvard Style

Ridwansyah, H., Kartamihardja, . A. H. S., Bashari, . M. H. & Hernowo, . B. S. (2021) The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. SRP, 12 (1), 935-947. doi:10.31838/srp.2021.1.131



Turabian Style

Ridwansyah, Hastono, Achmad Hussein S. Kartamihardja, Muhammad Hasan Bashari, and Bethy Suryawathy Hernowo. 2021. The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. Systematic Reviews in Pharmacy, 12 (1), 935-947. doi:10.31838/srp.2021.1.131



Chicago Style

Ridwansyah, Hastono, Achmad Hussein S. Kartamihardja, Muhammad Hasan Bashari, and Bethy Suryawathy Hernowo. "The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review." Systematic Reviews in Pharmacy 12 (2021), 935-947. doi:10.31838/srp.2021.1.131



MLA (The Modern Language Association) Style

Ridwansyah, Hastono, Achmad Hussein S. Kartamihardja, Muhammad Hasan Bashari, and Bethy Suryawathy Hernowo. "The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review." Systematic Reviews in Pharmacy 12.1 (2021), 935-947. Print. doi:10.31838/srp.2021.1.131



APA (American Psychological Association) Style

Ridwansyah, H., Kartamihardja, . A. H. S., Bashari, . M. H. & Hernowo, . B. S. (2021) The Potency of Radiolabelled Monoclonal Antibody Anti-CD20 as A Targeted Therapy for B-cell Non-Hodgkin Lymphoma: A Review. Systematic Reviews in Pharmacy, 12 (1), 935-947. doi:10.31838/srp.2021.1.131

Most Viewed Articles
  • Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01
  • Psychometric properties of the World Health Organization Quality of life instrument, short form: Validity in the Vietnamese healthcare context Trung Quang Vo*, Bao Tran Thuy Tran, Ngan Thuy Nguyen, Tram ThiHuyen Nguyen, Thuy Phan Chung Tran SRP. 2020; 11(1): 14-22 » doi: 10.5530/srp.2019.1.3
  • A Review of Pharmacoeconomics: the key to “Healthcare for All” Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21
  • Deuterium Depleted Water as an Adjuvant in Treatment of Cancer Anton Syroeshkin, Olga Levitskaya, Elena Uspenskaya, Tatiana Pleteneva, Daria Romaykina, Daria Ermakova SRP. 2019; 10(1): 112-117 » doi: 10.5530/srp.2019.1.19
Most Downloaded
  • Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01
  • Manilkara zapota (L.) Royen Fruit Peel: A Phytochemical and Pharmacological Review Karle Pravin P, Dhawale Shashikant C SRP. 2019; 10(1): 11-14 » doi: 0.5530/srp.2019.1.2
  • Pharmacognostic and Phytopharmacological Overview on Bombax ceiba Pankaj Haribhau Chaudhary, Mukund Ganeshrao Tawar SRP. 2019; 10(1): 20-25 » doi: 10.5530/srp.2019.1.4
  • A Review of Pharmacoeconomics: the key to “Healthcare for All” Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21
  • A Prospective Review on Phyto-Pharmacological Aspects of Andrographis paniculata Govindraj Akilandeswari, Arumugam Vijaya Anand, Palanisamy Sampathkumar, Puthamohan Vinayaga Moorthi, Basavaraju Preethi SRP. 2019; 10(1): 15-19 » doi: 10.5530/srp.2019.1.3